Blog

teamwork-dim-modern-labb

CBD vs CBG: difference, health benefits

July 18, 2021
While CBD products pique consumer interest, scientists came to light another very high-end cannabinoid, i.e., CBG. The discovery of the health benefits of CBG made it hard for consumers to select between two, i.e., CBG and CBD. Consumers of cannabinoids may be wondering which one is best ...Read More
cannabis legalization

The global march towards legalization of cannabis

March 24, 2021
In the united states, the legalization of cannabis is an important societal trend and a hot topic for debate. Cannabis is listed as a “Schedule I” drug due to its high potential for abuse and no accepted medical use. Cannabis producers and investors are keen to know when ...Read More
antioxidant

Astaxanthin: An Antioxidant

March 12, 2021
Compounds such as astaxanthin pique market interest due to their ability to efficiently act on various diseases’ molecular targets. The astaxanthin (ASX) market is projected to grow significantly to USD 814.1 million by 2022. Astaxanthin gained commercial customer attraction due to its expanding end-use applications. It is ...Read More
THCA

What is THCA? Can THCA get you high?

February 22, 2021
The cannabis plant contains hundreds of components that are called cannabinoids. These cannabinoids are present in varying concentrations in a cannabis plant. While many cannabinoids are in use by humans for decades, recent research found some rare cannabinoids, including THCA. With the boom of the cannabis market, you must have ...Read More
Astaxanthin by BioMedican

Astaxanthin: Food for animal and marine life

February 11, 2021
Recent research studies have demonstrated the importance of carotenoids in human health. These carotenoids play essential roles in regulating immunity, reproduction, cancer, age-related macular degeneration, and atherosclerosis. While these studies’ main focus was β-carotene, lutein, and lycopene, there is another compound, astaxanthin, a ketocarotenoid, that is increasingly ...Read More
THCV

What is THCV? How THCV is different from THC?

January 27, 2021
THCV or tetrahydrocannabivarin is a minor cannabinoid found in lower concentrations than the more common cannabinoids CBD and THC. THCV’s unique array of effects and medical benefits differ this compound from other cannabinoids. This minor cannabinoid is also initially produced from tetrahydrocannabivarin acid (THCVA) like CBD and THC ...Read More
cannabinol

What is Cannabinol(CBN)? Is CBN an inactive cannabinoid?

January 14, 2021
Cannabinoids such as D9 -tetrahydrocannabinol (THC) and cannabidiol (CBD) have gained significant interest due to beneficial/therapeutic effects for a series of syndromes, including Dravet syndrome, epilepsy, anxiety, schizophrenia, chronic pain, even for cancer, as well as for recreational purposes, e.g. euphoria. Other than the two most popular cannabinoids ...Read More
Biomedican - Cannabigerol CBG

What is CBG? Which is better CBD or CBG?

December 16, 2020
Although cannabidiol (CBD) is one of the most popular forms of medical cannabis, research suggests that cannabigerol (CBG), another molecule found in cannabis plants, also offers significant and unique health benefits. What is CBG?  CBG is one of over 120 cannabinoids, which have been discovered within the Cannabis sativa plant ...Read More
Biomedican Astaxanthin

What is Astaxanthin? What is it used for?

December 2, 2020
A rich, red nutrient called Astaxanthin has become increasingly popular due to its myriad of health benefits. Astaxanthin is naturally found within plants and is part of the family of micronutrients known as carotenoids. It is a powerful antioxidant that can support skin, heart, and brain health. What is astaxanthin ...Read More
Biomedican - biosynthetic platform

What is a Biosynthetic Platform?

November 24, 2020
A biosynthetic platform uses the principles of synthetic biology to generate a product. Synthetic biology is defined as “a field of science that involves redesigning organisms for useful purposes by engineering them to have new abilities.” This technique has allowed scientists and engineers to make great advances, including: Modification of ...Read More
Invest in cannabis

Why invest in socially responsible cannabis?

November 12, 2020
Cannabis continues to be one of the fastest-growing industries globally. In the United States alone, 11 states have legalized cannabis completely. 37 other states have legalized it for medical use (with limits on THC content). It is predicted that the global market for cannabinoid-based pharmaceuticals will reach $50 ...Read More
Biomedican - yeast fermentation

Biosynthesis of cannabinoids vs. chemical synthesis

October 12, 2020
What is the biosynthesis of cannabinoids? Biosynthesis is the process in which naturally occurring reagents and catalysts are used to create compounds identical to those found in nature. Biosynthesis of cannabinoids allows their production to be faster, cost-effective, and more sustainable than alternative methods. Biosynthetic cannabinoids grow through naturally ...Read More
Biomedican - yeast

How to grow rare cannabinoids in yeast

September 10, 2020
Cannabinoids are naturally occurring compounds found in the Cannabis sativa plant. As we’ve discussed in one of our previous blogs, these compounds have immense potential for consumer products and unique medicinal benefits. However, as we talked, rare cannabinoids occur naturally in the plant Cannabis sativa, but in extremely small ...Read More
Biomedican - cannabinoids guide

Rare cannabinoids: discover the endless health benefits

August 10, 2020
Which associations pop up in your mind when you hear the word “cannabis”? While many people still think of it as a recreational drug, this perception is not accurate and very limited. Following its legalization, the cannabinoid industry has been garnering a lot of attention in recent years ...Read More
minor cannabinoids

Beyond CBD, THC: ‘Minor’ Cannabinoids Flood Market-MEDPAGETODAY

May 10, 2021
Ryan Basen recently published an article, “Beyond CBD, THC: ‘Minor’ Cannabinoids Flood Market,” in MEDPAGETODAY. In the article, Ryan Basen elaborated on the rise of consumer use of minor cannabinoids, specifically delta-8 THC, and the lack of scientific evidence. Ryan highlighted BioMedican‘s aim ...Read More
Psychedelic

Expert-the covid-19 pandemic became a mental health epidemic causing surge in interest in psychedelic medicine-Pharmacy Times

April 22, 2021
Pharmacy Times recently published an interview of Dennis O’ Neill, president and board member of Biomedican, in which he gave his expert opinion over the booming medical psychedelic market and potential mental health benefits of medical psychedelics in the covid-19 pandemic. Dennis O’ Neill discussed how the covid-19 ...Read More
Biomedican- Cosmetics

Cannabinoids, Cosmetics, and Why CBD is Only the Beginning

April 15, 2021
A recent interview article, Cannabinoids, Cosmetics, and Why CBD is Only the Beginning, published in AZ Foothills Magazine, highlighted the importance of CBD in cosmetics. Tyler Hollis, the author of the article, asked Dennis O’Neill’s insight over prevalent skin and hair conditions and their potential prevention and treatment ...Read More
secondary listings

Hong Kong’s healthy pipeline of TMT secondary listings- S&P Global Market Intelligence

March 31, 2021
Xiuxi Zhu, Priyanka Boghani, and Stefen Joshua Rasay recently published an article, “Hong Kong’s healthy pipeline of TMT secondary listings,” in S&P Global Market Intelligence. The authors explained why the Hong Kong Stock Exchange is best for secondary investments and mentioned requirements to list ...Read More
Astaxanthin antioxidant

How We Used Biosynthesis to Produce the World’s Strongest Antioxidant

March 27, 2021
In a recent article, “How We Used Biosynthesis to Produce the World’s Strongest Antioxidant,” published in Healthcare Business Today, Maxim Mikheev introduced BioMedican‘s new biosynthesis platform for astaxanthin production to the world. BioMedican decided to diversify its product line with a high-value compound ...Read More
Maxim Mikheev at chemistry world.

The life of a chief scientific officer- Chemistry World

March 20, 2021
In a recent article, “The life of a chief scientific officer,” published in Chemistry World,  Dinsa Sachan appreciated the struggles and achievements of Max Mikheev, chief executive and chief science officer of Biomedican. Dinsa listed Max among the top chief scientific officers (CSOs) whose appetite for risk and ...Read More
Environmental

Reduce Environmental Impact of Cannabinoid Production Through Biosynthesis

March 14, 2021
In a recent article, “Reduce Environmental Impact of Cannabinoid Production Through Biosynthesis,” published in Cannabis Industry Journal, Maxim Mikheev highlighted a few significant differences between cannabinoids production through biosynthesis and conventional cultivation method. Maxim Mikheev explained why the biosynthesis method is more environmentally sustainable than commercial-scale cultivation. The immense ...Read More
Cannabiz: How to Invest in This Growing Industry

Cannabiz: How to Invest in This Growing Industry

February 28, 2021
A recent article, “Cannabiz: How to Invest in This Growing Industry,” published in The Ticker Tape, highlighted that recent growth and legalization chances of the cannabis industry potentially attract new investors. The author of the article, Matt Whittaker, analyzed the growth of marijuana stocks in 2020 and associated ...Read More
Fermentation by BioMedican

Startup claims fermentation expertise will provide a differentiator in production of rare cannabinoids

February 27, 2021
An article, “Startup claims fermentation expertise will provide a differentiator in production of rare cannabinoids,” published in Nutra-ingredients, introduced BioMedican to the world as a research-based biotech startup seeking to splash in hemp space with rare cannabinoids. The author and editor of the article, Hank Schultz, highlighted the ...Read More
investing in cannabis

How Rare Cannabinoids Will Impact Investing

February 20, 2021
A recent article, “How Rare Cannabinoids Will Impact Investing,” published in Cannabis Industry Journal, gracefully uncovered the hidden truths about rare cannabinoids, their importance, and their impact on cannabis investors. Two important human pillars of Biomedican: Maxim Mikheev and Dennis O’Neill, cleared the confusion of cannabis market investors about ...Read More
biomedican

Three Methods to Produce Rare Cannabinoids: Cultivation, Chemical Synthesis, and Biosynthesis

February 14, 2021
A recent publication, “Three Methods to Produce Rare Cannabinoids: Cultivation, Chemical Synthesis, and Biosynthesis,” of BiofuelDigest successfully differentiated between cultivation, chemical synthesis, and biosynthesis. The writer of the article and Founder of BioMedican, Max Mikheev, highlighted BioMedican’s approach to biosynthesize rare cannabinoids from proprietary yeast Yarrowia ...Read More
Stocks and ETFs

Cannabis Market Experts Explain When To Consider Stocks And ETFs

February 7, 2021
The article “Cannabis Market Experts Explain When To Consider Stocks And ETFs,” recently published in The Fresh Toast, highlighted the rise of the cannabis market in 2021 and demonstrated the pros and cons of stocks and ETFs for cannabis investors. The author of the article, Andrew Ward, quoted ...Read More
Industry leaders say legalizing pot critical to stop black-market sales

Industry leaders say legalization of pot critical to stop black-market sales

January 20, 2021
In a recent article, “Industry leaders say legalizing pot critical to stop black-market sales,” published in News10, Giuliana Bruno reported the conflict of opinion between Governor Cuomo and Assemblyman Karl Brabenec regarding the legalization the recreational use of marijuana in New York. She also demonstrated the view of Dennis ...Read More
marijuana

Cuomo lays out a plan for marijuana legalization, says the industry will generate $300 million in tax revenue annually – Fox Business

January 19, 2021
A recent article, “Cuomo lays out a plan for marijuana legalization, says the industry will generate $300 million in tax revenue annually” was published in Fox Business in which Paul Best emphasized the need to legalize marijuana in New York. Paul Best quoted Dennis O’Neill’ ...Read More
MARKET SHARES

HempFusion shares jump 50% in TSX debut – Reuters

January 13, 2021
Reuters, an international news organization, reported increased demand for Hemp-based products after the coronavirus pandemic in its recent Article. A massive boost of about 50% in shares of Cannabis and hemp-based products has been observed, serving as a lighthouse for new companies. The Article also mentioned  Biomedican’s ...Read More
biomedican

Predictions for the Global Cannabinoid Market in 2021 – Cannabis Business Executive

January 11, 2021
Dennis O’Neill from Biomedican recently shared the expectations linked to the development of the Cannabis industry in his recent article “5 Predictions for the Global Cannabinoid Market in 2021,” published in Cannabis Business Executive. O’Neill specifically highlighted Biomedican’s approach to biosynthesize rare ...Read More
Biomedican on Forbes

Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products – Forbes

November 15, 2020
Forbes contributor, Amanda Siebert, analyzed the rise of rare cannabinoids, including CBG, CBN, and others in her recent article “Move Over CBD: Rare Cannabinoids Shaking Up Cannabis And Hemp Products.” As a part of this article, Max Mikheev and Dennis O’Neil of Biomedican shared our unique ...Read More
flowers-2469212_1920_38

Cannabinoids Beyond THC And CBD Pique Market Interest – Benzinga

November 9, 2020
In a recent article “Cannabinoids Beyond THC And CBD Pique Market Interest” published in Benzinga, Andrew Ward brought the less-known cannabinoids into the light. He regarded THC and CBD as “just the tip of a massive iceberg”. Dennis O’Neill, co-founder of Biomedican elaborated the importance of ...Read More
This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to backburner, what employers should know

This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to the backburner, what employers should know

November 4, 2020
An article “ This week’s most important N.J. cannabis stories: Industry event featuring Booker, hemp goes to the backburner, what employers should know” recently published by N.J. Cannabis Insider staff explained Biomedican’s approach to biosynthesize cannabinoids. Dennis O’Neill stated biosynthesis as a significant opportunity for Biomedican ...Read More
Biomedican on Bloomberg

Race Is On for Synthetic Cannabinoids – Bloomberg

November 4, 2020
In the recent article, “Race Is On for Synthetic Cannabinoids: Cannabis Weekly” published in Bloomberg, Tiffany Kary highlighted that increased demand and popularity of cannabis resulted in an increased race for production of synthetic rare cannabinoids. Some companies are scaling up efforts to engineer lesser-known cannabinoids such ...Read More